Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Images: A Strange Reaction After a Hyaluronic Acid Injection.
Piroth M, Fanjat Y, Cardot-Leccia N, Roux C, Passeron T. Piroth M, et al. Among authors: passeron t. Arthritis Rheumatol. 2024 Feb 5. doi: 10.1002/art.42818. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 38317300 No abstract available.
Outdoor clinical testing with reference sunscreens to determine differences in skin response between populations of different ethnicity: A combined data analysis from 128 subjects.
Granger C, Passeron T, Trullas C, Hosenally M, Sokeechand BN, Krutmann J, Lim HW. Granger C, et al. Among authors: passeron t. Photodermatol Photoimmunol Photomed. 2023 Sep;39(5):419-427. doi: 10.1111/phpp.12871. Epub 2023 Mar 13. Photodermatol Photoimmunol Photomed. 2023. PMID: 36867064
Evaluation of adapted dermocosmetic regimens for perimenopausal and menopausal women using an artificial intelligence-based algorithm and quality of life questionnaires: An open observational study.
Flament F, Jiang R, Delaunay C, Kerob D, Leclerc-Mercier S, Kosmadaki M, Roó E, Haag T, Passeron T, Zouboulis CC. Flament F, et al. Among authors: passeron t. Skin Res Technol. 2023 Jul;29(7):e13349. doi: 10.1111/srt.13349. Skin Res Technol. 2023. PMID: 37522490 Free PMC article.
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Among authors: passeron t. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
355 results